Related references
Note: Only part of the references are listed.Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Yu Feng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
Ying Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
Yue Shi et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2022)
Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer
Rebekah Rittberg et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report
Yuqi Wu et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges
Shujie Zhou et al.
CANCER LETTERS (2021)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Shaochuan Liu et al.
CELL DEATH & DISEASE (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Yinli Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases The FIRE-SCLC Cohort Study
Chad G. Rusthoven et al.
JAMA ONCOLOGY (2020)
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
Marcus Skribek et al.
CANCERS (2020)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
1482OOutcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
A S Mansfield et al.
ANNALS OF ONCOLOGY (2019)
1483PDPembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
S F Powell et al.
ANNALS OF ONCOLOGY (2019)
The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202
Y. Cheng et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M. Kluger et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
Chengying Xie et al.
CANCER SCIENCE (2018)
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Simon J. Dovedi et al.
CLINICAL CANCER RESEARCH (2017)
Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases
R. V. Lukas et al.
ANNALS OF ONCOLOGY (2017)
Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity
Pankaj Seth et al.
CANCER RESEARCH (2017)
Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments
Jennifer Ding et al.
CANCER BIOMARKERS (2017)
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
Anna Sophie Berghoff et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Revisiting the Mechanisms of CNS Immune Privilege
Antoine Louyeau et al.
TRENDS IN IMMUNOLOGY (2015)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy - A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group
PE Postmus et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
